Skip to main content
Log in

Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication

Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Although the non-vitamin K antagonist oral anticoagulants (NOACs) do not require routine monitoring, there are special circumstances in which laboratory measurement may be warranted. The objectives of this review are to summarize evidence on the influence of the NOACs on coagulation tests and provide practical guidance to clinicians on measurement and interpretation of coagulation assays in NOAC-treated patients. Selection of an appropriate assay for NOAC measurement depends on the drug, clinical objective, and assay availability. Separate suggestions for assay selection are provided depending on whether specialized assays are available or whether choice is limited to conventional coagulation assays such as the prothrombin time (PT) and activated partial thromboplastin time (APTT). The dilute thrombin time (TT) and ecarin-based assays are able to quantify dabigatran across a broad range of concentrations, but are not widely available. A normal TT excludes clinically relevant levels. A normal APTT probably excludes excess levels of dabigatran, but does not rule out typical on-therapy drug concentrations. The PT is insufficiently sensitive to dabigatran to be useful in most situations. Factor Xa inhibitors may be quantified with an anti-Xa assay calibrated with drug-specific standards. A normal PT probably excludes excess levels of rivaroxaban and edoxaban, but not typical on-therapy levels of these agents. The PT is less sensitive to apixaban. Depending on the sensitivity of the thromboplastin reagent, a normal PT may not exclude excess levels of apixaban. The APTT has inadequate sensitivity to factor Xa inhibitors and is not recommended for their measurement.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Chai-Adisaksopha C, Crowther M, Isayama I, Lim W (2014) The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 124:2450–2458

    Article  CAS  PubMed  Google Scholar 

  2. Ezekowitz MD, Reilly PA, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-Azad K, Pedersen KE, Lionetti DA, Stangier J, Wallentin L (2007) Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 100:1419–1426

    Article  CAS  PubMed  Google Scholar 

  3. Mueck W, Stampfuss J, Kubitza D, Becka M (2014) Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 53:1–16

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Kowalsk K, Nielsen J, Roy A, et al (2014) Apixaban exposure and anti-Xa activity in nonvalvular atrial fibrillation patients: an application of population PK/PD analysis [abstract]. J Pharmacokinet Pharmacodyn 41:S19. Abstract M-027

  5. Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, Kastrissios H, Jin J, Kunitada S (2010) Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 104:633–641

    Article  CAS  PubMed  Google Scholar 

  6. Chan NC, Coppens M, Hirsh J, Ginsberg JS, Weitz JI, Vanassche T, Douketis J, Schulman S, Eikelboom JW (2015) Real-world variability in dabigatran levels in patients with atrial fibrillation. J Thromb Haemost 13:353–359

    Article  CAS  PubMed  Google Scholar 

  7. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L, Investigators RE-LY (2014) The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (randomized evaluation of long-term anticoagulation therapy). J Am Coll Cardiol 63:321–328

    Article  CAS  PubMed  Google Scholar 

  8. Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, Deenadayalu N, Jarolim P, Betcher J, Shi M, Brown K, Patel I, Mercuri M, Antman EM (2015) Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 385:2288–2295

    Article  CAS  PubMed  Google Scholar 

  9. Cuker A, Siegal DM (2015) Monitoring and reversal of direct oral anticoagulants. Hematol Am Soc Hematol Educ Progr

  10. Cuker A, Siegal DM, Crowther MA, Garcia DA (2014) Laboratory measurement of the anticoagulant activity of the non-vitamin K antagonist oral anticoagulants. J Am Coll Cardiol 64:1128–1139

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Cuker A, Husseinzadeh H (2015) Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review. J Thromb Thrombolysis 39:288–294

    Article  CAS  PubMed  Google Scholar 

  12. Bonar R, Favaloro EJ, Mohammed S, Pasalic L, Sioufi J, Marsden K (2015) The effect of dabigatran on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. Pathology 47:355–364

    Article  PubMed  Google Scholar 

  13. Hawes EM, Deal AM, Funk-Adcock D, Gosselin R, Jeanneret C, Cook AM, Taylor JM, Whinna HC, Winkler AM, Moll S (2013) Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost 11:1493–1502

    Article  CAS  PubMed  Google Scholar 

  14. Favaloro EJ, Bonar R, Butler J, Marsden K (2013) Laboratory testing for new oral anticoagulants: a review of current practice. Pathology 45:435–437

    Article  PubMed  Google Scholar 

  15. Douxfils J, Mullier F, Robert S, Chatelain C, Dogné JM (2012) Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 107:985–997

    Article  CAS  PubMed  Google Scholar 

  16. Harenberg J, Giese C, Marx S, Krämer R (2012) Determination of dabigatran in human plasma samples. Semin Thromb Hemost 38:16–22

    Article  CAS  PubMed  Google Scholar 

  17. Antovic JP, Skeppholm M, Eintrei J, Boija EE, Söderblom L, Norberg EM, Onelöv L, Rönquist-Nii Y, Pohanka A, Beck O, Hjemdahl P, Malmström RE (2013) Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. Eur J Clin Pharmacol 69:1875–1881

    Article  CAS  PubMed  Google Scholar 

  18. Jones SD, Eaddy NS, Chan GT (2012) Dabigatran: laboratory monitoring. Pathology 44:578–580

    Article  PubMed  Google Scholar 

  19. Hapgood G, Butler J, Malan E, Chunilal S, Tran H (2013) The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. Thromb Haemost 110:308–315

    Article  CAS  PubMed  Google Scholar 

  20. Helin TA, Pakkanen A, Lassila R, Joutsi-Korhonen L (2013) Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories. Clin Chem 59:807–814

    Article  CAS  PubMed  Google Scholar 

  21. Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W (2013) Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standarisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. doi:10.1111/jth.12149

    Google Scholar 

  22. Molenaar PJ, Dinkelaar J, Leyte A (2012) Measuring rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation. Clin Chem Lab Med 50:1799–1807

    Article  CAS  PubMed  Google Scholar 

  23. Douxfils J, Tamigniau A, Chatelain B, Chatelain C, Wallemacq P, Dogné JM, Mullier F (2013) Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost 110:723–731

    Article  CAS  PubMed  Google Scholar 

  24. Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, Kunitada S (2010) Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 50:743–753

    Article  CAS  PubMed  Google Scholar 

  25. Wolzt M, Samama MM, Kapiotis S, Ogata K, Mendell J, Kunitada S (2011) Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux. Thromb Haemost 105:1080–1090

    Article  CAS  PubMed  Google Scholar 

  26. Gosselin RC, Francart SJ, Hawes EM, Moll S, Dager WE, Adcock DM (2015) Heparin-calibrated chromogenic anti-Xa activity measurements in patients receiving rivaroxaban: can this test be used to quantify drug level? Ann Pharmacother 49:777–783

    Article  CAS  PubMed  Google Scholar 

  27. College of American Pathologists (2013) Surveys Participant Summary for CGE, CGL, GCS, and ACM. College of American Pathologists, Northfield

    Google Scholar 

  28. Zafar MU, Vorchheimer DA, Gaztanaga J, Velez M, Yadegar D, Moreno PR, Kunitada S, Pagan J, Fuster V, Badimon JJ (2007) Antithrombotic effects of factor Xa inhibition with DU-176b: phase-I study of an oral, direct factor Xa inhibitor using an ex vivo flow chamber. Thromb Haemost 98:883–888

    CAS  PubMed  Google Scholar 

  29. Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, Perzborn E (2010) Assessment of laboratory assays to measure rivaroxaban—an oral, direct factor Xa inhibitor. Thromb Haemost 103:815–825

    Article  CAS  PubMed  Google Scholar 

  30. Tripodi A, Chantarangkul V, Guinet C, Samama MM (2011) The international normalized ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. J Thromb Haemost 9:226–228

    Article  CAS  PubMed  Google Scholar 

  31. Samama MM, Contant G, Spiro TE, Perzborn E, Flem LL, Guinet C, Gourmelin Y, Martinoli JL, Laboratories Rivaroxaban Prothrombin Time Field Trial (2012) Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial. Clin Appl Thromb Hemost 18:150–158

    Article  CAS  PubMed  Google Scholar 

  32. Samama MM, Mendell J, Guinet C, Le Flem L, Kunitada S (2012) In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thromb Res 129:e77–e82

    Article  CAS  PubMed  Google Scholar 

  33. Tripodi A, Padovan L, Veena C, Scalambrino E, Testa S, Peyvandi F (2015) How the direct oral anticoagulant apixaban affects thrombin generation parameters. Thromb Res 135:1186–1190

    Article  CAS  PubMed  Google Scholar 

  34. Francart SJ, Hawes EM, Deal AM, Adcock DM, Gosselin R, Jeanneret C, Friedman KD, Moll S (2014) Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamics study based on peak and trough plasma levels. Thromb Haemost 111:1133–1140

    Article  CAS  PubMed  Google Scholar 

  35. Barrett YC, Wang Z, Knabb RM (2013) A novel prothrombin time assay for assessing the anticoagulant activity of oral factor Xa inhibitors. Clin Appl Thromb Hemost 19:522–528

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Adam Cuker.

Ethics declarations

Conflict of interest

AC has served as a consultant for Amgen, Bracco, CSL Behring, and Genzyme and has received research support from T2 Biosystems.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cuker, A. Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication. J Thromb Thrombolysis 41, 241–247 (2016). https://doi.org/10.1007/s11239-015-1282-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-015-1282-7

Keywords

Navigation